Pfizer has said it will sell more of its cancer products than primary care medicines in 2019 and EvaluatePharma expects the products to help generate sales of $ 8.3bn . Fresh knowledge about the risks of cancer has led to new treatments and Pfizer said it was committed to expanding its oncology products . EvaluatePharma ##cological cancer drug sales would reach $ 138bn globally during 2019 and are increasing at 11 % each year . Five of Pfizer ’s last seven cancer drugs were approved without a late - stage trial and its biggest oncology treatment , however , saw sales of almost $ 3bn in the first nine months of 2018 .
Pfizer has said it will sell more of its oncology products than primary care medicines in 2019 and EvaluatePharma expects the products to help generate sales of $8.3bn. Fresh knowledge about the biology of cancer has led to new treatments and Pfizer said it was committed to expanding its oncology products. EvaluatePharma said cancer drug sales would reach $138bn globally during 2019 and are growing at 11% each year. Five of Pfizer’s last seven cancer drugs were approved without a late-stage trial and its biggest oncology treatment, Ibrance, saw sales of almost $3bn in the first nine months of 2018.